Validation of commercial dry-form broth microdilution panels and test reproducibility for susceptibility testing of dalbavancin, a new very long-acting glycopeptide
- 1 February 2004
- journal article
- research article
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 23 (2) , 197-199
- https://doi.org/10.1016/j.ijantimicag.2003.07.008
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Validation of commercial dry-form broth microdilution panels for susceptibility testing of AZD2563, a new long-acting oxazolidinoneClinical Microbiology & Infection, 2003
- Initial Quality Control Evaluations for Susceptibility Testing of Dalbavancin (BI397), an Investigational Glycopeptide with Potent Gram-Positive ActivityJournal of Clinical Microbiology, 2003
- In VitroEvaluation of BI 397, a Novel Glycopeptide Antimicrobial AgentJournal of Chemotherapy, 2001
- OxazolidinonesDrugs, 2000
- In-vitro and in-vivo antibacterial activity of BI 397, a new semi-synthetic glycopeptide antibioticJournal of Antimicrobial Chemotherapy, 1999
- Antimicrobial Activity of Quinupristin-Dalfopristin (RP 59500, Synercid®) Tested against Over 28,000 Recent Clinical Isolates from 200 Medical Centers in the United States and CanadaDiagnostic Microbiology and Infectious Disease, 1998
- Gram-positive resistance: challenge for the development of new antibioticsJournal of Antimicrobial Chemotherapy, 1997
- Antimicrobial activity of MDL 63,246, a new semisynthetic glycopeptide antibioticAntimicrobial Agents and Chemotherapy, 1995